Clinical Trials Browser

dostarlimab × Gynecologic × Clear all

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT05277051 2026-03-23

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05819892 2026-03-11

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04774419 2026-02-03

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Phase 2 Recruiting

Endometrial Neoplasms

NCT07336147 2026-01-14

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT06238635 2026-01-13

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03955978 2026-01-06

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT03651206 2025-12-19

ROCSAN

Phase 2/3 Recruiting

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT07115927 2025-08-19

RODEO

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT06897527 2025-07-08

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Phase 4 Not yet recruiting

Endometrial Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT07013851 2025-06-10

NADIA

Phase 2 Not yet recruiting

GynecologicOther solid neoplasm

MMRd/MSI-H Stage II-III Endometrial Cancer

NCT03833479 2025-05-21

ATOMICC

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06385548 2025-04-01

LiDer

Phase 1/2 Withdrawn

Endometrial Neoplasms

NCT06278857 2024-12-03

SATELLITE

Phase 2 Recruiting

Turcot syndrome, Endometrial Neoplasms

NCT03250832 2024-04-11

CITRINO

Phase 1 Completed

111 enrolled 48 charts

GastrointestinalGynecologicThoracic

Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT05728814 2024-02-23

DORA

Endometrial Neoplasms

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2 Unknown

Endometrial Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05751629 2023-04-21

COHORT-A

Phase 2 Completed

41 enrolled 17 charts

Ovarian Neoplasms

NCT05405192 2023-02-28

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Phase 2 Withdrawn

Gestational Trophoblastic Disease

NCT03955471 2022-09-10

MOONSTONE

Phase 2 Terminated

41 enrolled 22 charts

Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

Phase 3 Unknown

Ovarian Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Ovarian Neoplasms